Key result
Angiopoietin-2 promoted endothelial cell survival and attenuated apoptosis through ERK1/2 and PI3-kinase pathways, but did not affect cell migration.
Ang-2 promotes endothelial cell survival via ERK1/2 and PI3-kinase pathways but does not strongly promote cell migration, differing from Ang-1 in its interaction with VEGF.
Answers are grounded in this paper and cite their sources.
May inform endothelial protection research in vascular models; leaves open differential Ang-2 therapeutic roles versus Ang-1 pending in vivo validation.
Angiopoietins are ligands for endothelial cell-specific Tie-2 receptors. Whereas angiopoietin-1 (Ang-1) activates these receptors and promotes cell survival, migration, and sprouting, little information is available regarding how Ang-2 influences these cells. In this study, we evaluated signaling pathways and biological effects of physiological concentrations of Ang-2 in cultured human umbilical vein endothelial cells. Ang-2 at 150 and 300 ng/ml elicited a transient (reaching peak values within 15 min of exposure) increase in the phosphorylation of Tie-2 receptors, protein kinase B (Akt), ERK1/2, and p38 members of the mitogen-activated protein kinases. However, unlike Ang-1, Ang-2 significantly inhibited JNK/SAPK phosphorylation. When vascular endothelial growth factor (VEGF) was present along with Ang-2, ERK1/2 phosphorylation was inhibited, whereas augmentation of Ang-1-induced ERK1/2 phosphorylation was triggered by VEGF. Ang-2 treatment had no effect on cell migration and in vitro wound healing but significantly attenuated serum deprivation-induced apoptosis and promoted survival. These effects were completely reversed by phosphatidylinositol 3 (PI3)-kinase and ERK1/2 inhibitors but were augmented by an inhibitor of the p38 pathway. These results suggest that Ang-2 promotes endothelial cell survival through the ERK1/2 and PI3-kinase pathways and that this angiopoietin is not a strong promoter of endothelial cell migration. We also conclude that the nature of interactions in terms of ERK1/2 activation between Ang-2 and VEGF is different from that of Ang-1 and VEGF.
No takes yet. Share an insight, caveat, or question.
Harfouche et al. (2006) studied this question. Angiopoietin-2 was evaluated on Cell survival, migration, and signaling pathway phosphorylation. Angiopoietin-2 promoted endothelial cell survival and attenuated apoptosis through ERK1/2 and PI3-kinase pathways, but did not affect cell migration.
Synapse has enriched 10 related papers. Consider them for comparative context: